<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01733953</url>
  </required_header>
  <id_info>
    <org_study_id>1207M17202</org_study_id>
    <nct_id>NCT01733953</nct_id>
  </id_info>
  <brief_title>Statin Therapy in Young Adult Survivors of Childhood Cancer</brief_title>
  <official_title>Pilot Study of Statin Therapy in Young Adult Survivors of Childhood Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adult survivors of childhood cancer are at high risk of developing cardiovascular disease.&#xD;
      Therapies used to treat many cancers, such as chemotherapy and radiation, likely cause damage&#xD;
      to the surface of the artery wall called the endothelial layer, leading to the induction of&#xD;
      atherosclerosis and eventual cardiovascular disease. HMG coenzyme A reductase inhibitors, or&#xD;
      statins, improve endothelial function independent of cholesterol-lowering. In addition,&#xD;
      statins have been shown to reduce arterial stiffness and slow arterial thickening. Despite&#xD;
      strong evidence supporting the vascular benefits of statins in many different patient&#xD;
      populations, these medications have never been studied in cancer survivors. Therefore, the&#xD;
      overall objective of this study is to evaluate the effects of statin therapy on vascular&#xD;
      health in young adult survivors of childhood cancer.&#xD;
&#xD;
      Twenty-four young adult (age 18-39 years old) survivors of childhood acute lymphoblastic&#xD;
      leukemia (ALL) or non-Hodgkin's lymphoma (NHL) will be enrolled in a six-month randomized,&#xD;
      double-blind (participants and investigators), placebo-controlled pilot clinical trial&#xD;
      comparing the effects of atorvastatin versus placebo on endothelial function and other&#xD;
      measures of vascular health.&#xD;
&#xD;
      Our primary objective is to evaluate the effects of 6-months of statin therapy on conduit&#xD;
      artery endothelial function in young adult survivors of childhood cancer. The investigators&#xD;
      hypothesize that, compared to placebo, atorvastatin will significantly increase brachial&#xD;
      artery flow-mediated dilation in survivors of childhood acute lymphoblastic leukemia and&#xD;
      non-Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adult survivors of childhood cancer are at seven times the risk of dying from cardiovascular&#xD;
      disease compared to the general population. The increased risk is thought to be the result of&#xD;
      the therapies used to treat the cancer such as chemotherapy and radiation. These therapies&#xD;
      likely cause damage to the endothelial cells, which line the arterial wall and, when function&#xD;
      properly, offer protection from atherosclerosis. Young adult survivors of childhood ALL have&#xD;
      reduced endothelial function, or endothelial dysfunction, compared to healthy controls.&#xD;
      Endothelial dysfunction is considered an early manifestation of atherosclerosis and therefore&#xD;
      is an ideal target of therapy in order to reduce the risk of cardiovascular disease.&#xD;
      Interventions that improve endothelial function in young adult survivors of childhood cancer&#xD;
      may be beneficial in terms of mitigating the medium- and long-term risk of developing this&#xD;
      chronic disease.&#xD;
&#xD;
      HMG coenzyme A reductase inhibitors, or statins, are widely used for cardiovascular disease&#xD;
      risk reduction. These medications are primarily used to reduce levels of total- and&#xD;
      low-density lipoprotein (LDL) -cholesterol. Meta-analyses have consistently demonstrated that&#xD;
      statin therapy improves endothelial function in a wide array of patient populations. Beyond&#xD;
      their well-described vascular benefits, statins are an attractive therapeutic option for&#xD;
      cardiovascular disease risk reduction due to their strong safety profile.&#xD;
&#xD;
      Despite the clear potential for endothelial function improvement and cardiovascular risk&#xD;
      reduction, statin therapy has never been evaluated in survivors of childhood cancer. Although&#xD;
      statins have been well-studied in other patient populations at risk for cardiovascular&#xD;
      disease, there is strong justification for evaluation in cancer survivors since the&#xD;
      mechanisms responsible for the vascular problems in these individuals (treatment-induced&#xD;
      vascular toxicity) differ from traditional atherosclerosis. Therefore, the objective of the&#xD;
      current study is to assess the ability of statin therapy to improve endothelial function,&#xD;
      arterial stiffness, and arterial thickening in young adult survivors of childhood cancer. The&#xD;
      focus of the study will be on survivors of hematologic malignancies, acute lymphoblastic&#xD;
      leukemia (ALL) and non-Hodgkin's lymphoma (NHL), since the former has been shown to be&#xD;
      associated with endothelial impairments and both cancers share common treatment exposures&#xD;
      (chemotherapy and radiation), which is likely the primary factor responsible for endothelial&#xD;
      dysfunction in these individuals.&#xD;
&#xD;
      Twenty-four young adult (age 18-39 years old) survivors of childhood acute lymphoblastic&#xD;
      leukemia (ALL) and non-Hodgkin's lymphoma (NHL)will be enrolled in a six-month randomized,&#xD;
      double-blind (participants and investigators), placebo-controlled pilot clinical trial&#xD;
      comparing the effects of atorvastatin versus placebo on endothelial function and other&#xD;
      measures of vascular health. Following baseline testing, subjects will be randomly assigned&#xD;
      (1:1) to either atorvastatin or placebo. Participants will return at 1-month and 3-months for&#xD;
      assessment of safety (blood draw and adverse event assessment) and medication compliance and&#xD;
      at 6-months for assessment of safety, medication compliance, and reassessment of baseline&#xD;
      variables.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Brachial Artery Flow-Mediated Dilation at 6-months</measure>
    <time_frame>Baseline and 6-Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Carotid Artery Compliance at 6-Months</measure>
    <time_frame>Baseline and 6-Months</time_frame>
    <description>Carotid Artery Compliance is a measure of arterial stiffness. Higher arterial stiffness places persons at higher risk for CVD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Carotid Artery Distensibility at 6-Months</measure>
    <time_frame>Baseline and 6-Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pulse Wave Velocity at 6-Months</measure>
    <time_frame>Baseline and 6-Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Augmentation Index at 6-Months</measure>
    <time_frame>Baseline and 6-Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Carotid Intima-Media Thickness at 6-Months</measure>
    <time_frame>Baseline and 6-Months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Cardiovascular Disease</condition>
  <condition>Childhood ALL</condition>
  <condition>Childhood NHL</condition>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6-Months Atorvastatin Therapy; 40mg oral, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar Pill (Placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>6-Months Placebo (sugar pill); oral, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>6-Months of Atorvastatin (Lipitor); 40mg, oral, once daily.</description>
    <arm_group_label>Atorvastatin</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugar Pill (Placebo)</intervention_name>
    <description>6-Months of placebo (sugar) pill; oral, once daily</description>
    <arm_group_label>Sugar Pill (Placebo)</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Survivor of childhood acute lymphoblastic leukemia (ALL) or non-Hodgkins's lymphoma&#xD;
             (NHL) (treated for ALL or NHL before the age of 21 years old and ≥5 years&#xD;
             post-treatment)&#xD;
&#xD;
          -  18-39 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 or 2 diabetes mellitus&#xD;
&#xD;
          -  Prior treatment with hematopoietic stem cell transplant&#xD;
&#xD;
          -  Low-density lipoprotein (LDL) -cholesterol ≥130 mg/dL (individuals with elevated&#xD;
             LDL-cholesterol will be referred for clinical management of dyslipidemia)&#xD;
&#xD;
          -  Alanine transaminase (ALT), Aspartate transaminase (AST), or Creatine kinase (CK)&#xD;
             greater than 2 times the upper limit of normal&#xD;
&#xD;
          -  Current or recent (within 6-months) use of lipid-lowering medication&#xD;
&#xD;
          -  Recent initiation (within 6-months) of anti-hypertensive medication (individuals on&#xD;
             stable therapy may be enrolled)&#xD;
&#xD;
          -  Current or recent (within 6-months) use of fibric acid derivatives, lipid-modifying&#xD;
             doses of niacin, cyclosporine or strong CYP3A4 inhibitors (i.e. clarithromycin, HIV&#xD;
             protease inhibitors, and itraconazole)&#xD;
&#xD;
          -  Pregnant, lactating or planning to become pregnant&#xD;
&#xD;
          -  Liver/renal dysfunction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aaron S Kelly, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>November 20, 2012</study_first_submitted>
  <study_first_submitted_qc>November 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2012</study_first_posted>
  <results_first_submitted>April 11, 2016</results_first_submitted>
  <results_first_submitted_qc>August 19, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 14, 2016</results_first_posted>
  <last_update_submitted>October 28, 2016</last_update_submitted>
  <last_update_submitted_qc>October 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiovascular Disease</keyword>
  <keyword>Childhood ALL</keyword>
  <keyword>Childhood NHL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>At this time we have no plan to share the IPD.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Atorvastatin</title>
          <description>6-Months Atorvastatin Therapy; 40mg oral, once daily&#xD;
Atorvastatin: 6-Months of Atorvastatin (Lipitor); 40mg, oral, once daily.</description>
        </group>
        <group group_id="P2">
          <title>Sugar Pill (Placebo)</title>
          <description>6-Months Placebo (sugar pill); oral, once daily&#xD;
Sugar Pill (Placebo): 6-Months of placebo (sugar) pill; oral, once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Atorvastatin</title>
          <description>6-Months Atorvastatin Therapy; 40mg oral, once daily&#xD;
Atorvastatin: 6-Months of Atorvastatin (Lipitor); 40mg, oral, once daily.</description>
        </group>
        <group group_id="B2">
          <title>Sugar Pill (Placebo)</title>
          <description>6-Months Placebo (sugar pill); oral, once daily&#xD;
Sugar Pill (Placebo): 6-Months of placebo (sugar) pill; oral, once daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.6" spread="5.7"/>
                    <measurement group_id="B2" value="26.9" spread="6.9"/>
                    <measurement group_id="B3" value="26.8" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Brachial Artery Flow-Mediated Dilation at 6-months</title>
        <time_frame>Baseline and 6-Months</time_frame>
        <population>Physician withdrawals, loss to follow-up, drug compliance &lt;70%, unrelated injury, and self-withdrawal reduced number analyzed. Also, participant movement during FMD assessment and/or poor ultrasound image quality due to difficult brachial artery anatomy or poor circulation led to some unusable data and thus lowered the analyzable sample size.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>6-Months Atorvastatin Therapy; 40mg oral, once daily&#xD;
Atorvastatin: 6-Months of Atorvastatin (Lipitor); 40mg, oral, once daily.</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill (Placebo)</title>
            <description>6-Months Placebo (sugar pill); oral, once daily&#xD;
Sugar Pill (Placebo): 6-Months of placebo (sugar) pill; oral, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Brachial Artery Flow-Mediated Dilation at 6-months</title>
          <population>Physician withdrawals, loss to follow-up, drug compliance &lt;70%, unrelated injury, and self-withdrawal reduced number analyzed. Also, participant movement during FMD assessment and/or poor ultrasound image quality due to difficult brachial artery anatomy or poor circulation led to some unusable data and thus lowered the analyzable sample size.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" lower_limit="-2.9" upper_limit="1.9"/>
                    <measurement group_id="O2" value="-3.4" lower_limit="-7.3" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Carotid Artery Compliance at 6-Months</title>
        <description>Carotid Artery Compliance is a measure of arterial stiffness. Higher arterial stiffness places persons at higher risk for CVD.</description>
        <time_frame>Baseline and 6-Months</time_frame>
        <population>Discrepant sample sizes are due to lack of reliability of measures. If measures were unreliable they were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>6-Months Atorvastatin Therapy; 40mg oral, once daily&#xD;
Atorvastatin: 6-Months of Atorvastatin (Lipitor); 40mg, oral, once daily.</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill (Placebo)</title>
            <description>6-Months Placebo (sugar pill); oral, once daily&#xD;
Sugar Pill (Placebo): 6-Months of placebo (sugar) pill; oral, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Carotid Artery Compliance at 6-Months</title>
          <description>Carotid Artery Compliance is a measure of arterial stiffness. Higher arterial stiffness places persons at higher risk for CVD.</description>
          <population>Discrepant sample sizes are due to lack of reliability of measures. If measures were unreliable they were excluded.</population>
          <units>mm/mmHg x 10^-3</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.34" lower_limit="-1.4" upper_limit="0.7"/>
                    <measurement group_id="O2" value="0.57" lower_limit="-.8" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Carotid Artery Distensibility at 6-Months</title>
        <time_frame>Baseline and 6-Months</time_frame>
        <population>Discrepant sample sizes are due to lack of reliability of measures. If measures were unreliable they were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>6-Months Atorvastatin Therapy; 40mg oral, once daily&#xD;
Atorvastatin: 6-Months of Atorvastatin (Lipitor); 40mg, oral, once daily.</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill (Placebo)</title>
            <description>6-Months Placebo (sugar pill); oral, once daily&#xD;
Sugar Pill (Placebo): 6-Months of placebo (sugar) pill; oral, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Carotid Artery Distensibility at 6-Months</title>
          <population>Discrepant sample sizes are due to lack of reliability of measures. If measures were unreliable they were excluded.</population>
          <units>% distensibility</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" lower_limit="-1.28" upper_limit="1.9"/>
                    <measurement group_id="O2" value="0.33" lower_limit="-1.81" upper_limit="2.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pulse Wave Velocity at 6-Months</title>
        <time_frame>Baseline and 6-Months</time_frame>
        <population>Discrepant sample sizes are due to lack of reliability of measures. If measures were unreliable they were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>6-Months Atorvastatin Therapy; 40mg oral, once daily&#xD;
Atorvastatin: 6-Months of Atorvastatin (Lipitor); 40mg, oral, once daily.</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill (Placebo)</title>
            <description>6-Months Placebo (sugar pill); oral, once daily&#xD;
Sugar Pill (Placebo): 6-Months of placebo (sugar) pill; oral, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pulse Wave Velocity at 6-Months</title>
          <population>Discrepant sample sizes are due to lack of reliability of measures. If measures were unreliable they were excluded.</population>
          <units>m/s</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" lower_limit="-2.06" upper_limit="1.02"/>
                    <measurement group_id="O2" value="-0.3" lower_limit="-2.36" upper_limit="1.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Augmentation Index at 6-Months</title>
        <time_frame>Baseline and 6-Months</time_frame>
        <population>Discrepant sample sizes are due to lack of reliability of measures. If measures were unreliable they were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>6-Months Atorvastatin Therapy; 40mg oral, once daily&#xD;
Atorvastatin: 6-Months of Atorvastatin (Lipitor); 40mg, oral, once daily.</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill (Placebo)</title>
            <description>6-Months Placebo (sugar pill); oral, once daily&#xD;
Sugar Pill (Placebo): 6-Months of placebo (sugar) pill; oral, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Augmentation Index at 6-Months</title>
          <population>Discrepant sample sizes are due to lack of reliability of measures. If measures were unreliable they were excluded.</population>
          <units>P2/P1</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.66" lower_limit="-15.38" upper_limit="14.06"/>
                    <measurement group_id="O2" value="-6.01" lower_limit="-24.16" upper_limit="12.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Carotid Intima-Media Thickness at 6-Months</title>
        <time_frame>Baseline and 6-Months</time_frame>
        <population>Discrepant sample sizes are due to lack of reliability of measures. If measures were unreliable they were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>6-Months Atorvastatin Therapy; 40mg oral, once daily&#xD;
Atorvastatin: 6-Months of Atorvastatin (Lipitor); 40mg, oral, once daily.</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill (Placebo)</title>
            <description>6-Months Placebo (sugar pill); oral, once daily&#xD;
Sugar Pill (Placebo): 6-Months of placebo (sugar) pill; oral, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Carotid Intima-Media Thickness at 6-Months</title>
          <population>Discrepant sample sizes are due to lack of reliability of measures. If measures were unreliable they were excluded.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.01" lower_limit="-.03" upper_limit="0.01"/>
                    <measurement group_id="O2" value="0.01" lower_limit="-0.02" upper_limit="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Atorvastatin</title>
          <description>6-Months Atorvastatin Therapy; 40mg oral, once daily&#xD;
Atorvastatin: 6-Months of Atorvastatin (Lipitor); 40mg, oral, once daily.</description>
        </group>
        <group group_id="E2">
          <title>Sugar Pill (Placebo)</title>
          <description>6-Months Placebo (sugar pill); oral, once daily&#xD;
Sugar Pill (Placebo): 6-Months of placebo (sugar) pill; oral, once daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Cameron Naughton</name_or_title>
      <organization>University of Minnesota</organization>
      <phone>612-625-3623</phone>
      <email>naug0009@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

